Evidence map›Paper›PMID 39417192›Full record

ArticleAmerican journal of cancer research2024

Utidelone-based therapy in advanced or metastatic solid tumors after failure of standard therapies: a prospective, multicenter, single-arm trial.

Guanglei Qiao, Zimei Liu, Honghua Ding, Hongmin Lu, Feng Lin, Yang Shi, Leizhen Zheng, Mei Wang, Ying Chen, Zhoufeng Deng and 6 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07363330 (Utidelone Combined With Toripalimab in Patients With Pretreated Recurrent or Metastatic Cervical Cancers), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07363330 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Utidelone Combined With Toripalimab in Patients With Pretreated Recurrent or Metastatic Cervical Cancers: a Single-Arm, Phase II Study

TypeinterventionalSponsorZhongnan HospitalRan2026 to 2028Enrolled32ConditionsCervical Cancer, Recurrent, MetastaticArmsUtidelone plus Toripalimab
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Guanglei QiaoDepartment of Oncology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, China.
Zimei LiuDepartment of Oncology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, China.
Honghua DingDepartment of Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, China.
Hongmin LuDepartment of Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, China.
Feng LinDepartment of Oncology, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, China.
Yang ShiDepartment of Oncology, Shanghai Ninth People's Hospital Huangpu Branch, Shanghai Jiao Tong University Shanghai, China.
Leizhen ZhengDepartment of Oncology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, China.
Mei WangDepartment of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, China.
Ying ChenDepartment of Oncology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, China.
Zhoufeng DengDepartment of Oncology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, China.
Liping YuDepartment of Oncology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, China.
Yan ZhangDepartment of Oncology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, China.
Ying YuanDepartment of Oncology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, China.
Hongjian LinDepartment of Oncology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, China.
Lijun MaDepartment of Oncology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, China.
Jianjun ZhangDepartment of Oncology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment options are limited for tumors after failure of standard therapies. Utidelone (UTD1), a novel microtubule stabilizer, given via 5 days intermittent infusion, has demonstrated high activity in heavily pretreated metastatic breast cancer, while its efficacy in other cancers was unclear. Peripheral neuropathy is a common and severe adverse event (AE) of UTD1. We performed a prospective, multicenter, single-arm trial (ChiCTR2300074299) to evaluate the efficacy and safety of UTD1 with a changed administration mode in patients with advanced or metastatic solid tumors after failure of standard therapies. UTD1 (150 mg/m

Indexed as

drug resistancemetastatic cancerprogression-free survivalUtidelone

Identifiers

PMID39417192
PMCPMC11477828

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.